Edge Therapeutics
Total Raised
$101.55MInvestors Count
11Deal Terms
6Funding, Valuation & Revenue
11 Fundings
Edge Therapeutics has raised $101.55M over 11 rounds.
Edge Therapeutics's latest funding round was a IPO for $80.46M on October 1, 2015.
Edge Therapeutics's latest post-money valuation is from October 2015.
Sign up for a free demo to see Edge Therapeutics's valuations in October 2015 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
10/1/2015 | IPO | $80.46M | 1 | |||
4/9/2015 | Series C - II | $56M | 3 | |||
11/14/2014 | Series C | $16.5M | Undisclosed Investors | 1 | ||
9/8/2014 | Debt | |||||
6/4/2013 | Series B - III |
Date | 10/1/2015 | 4/9/2015 | 11/14/2014 | 9/8/2014 | 6/4/2013 |
|---|---|---|---|---|---|
Round | IPO | Series C - II | Series C | Debt | Series B - III |
Amount | $80.46M | $56M | $16.5M | ||
Investors | Undisclosed Investors | ||||
Valuation | |||||
Revenue | |||||
Sources | 1 | 3 | 1 |
Edge Therapeutics Deal Terms
6 Deal Terms
Edge Therapeutics's deal structure is available for 6 funding rounds, including their IPO from October 01, 2015.
Round | IPO | Series C - II | Debt | Series B - III | Series B - II |
|---|---|---|---|---|---|
Funding Date | |||||
Pre-Money Valuation | |||||
Post-Money Valuation | |||||
Amount Raised | |||||
Shares Authorized | |||||
Issuance Price | |||||
Dividend Rate | |||||
Liquidation Preferences | |||||
Liquidation Price | |||||
Participation | |||||
Conversion Price | |||||
Anti Dilution | |||||
General Voting | |||||
Board Voting | |||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO | |||||||||||||||
Series C - II | |||||||||||||||
Debt | |||||||||||||||
Series B - III | |||||||||||||||
Series B - II |
Edge Therapeutics Investors
11 Investors
Edge Therapeutics has 11 investors. New Leaf Venture Partners invested in Edge Therapeutics's Series C - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
4/9/2015 | 4/9/2015 | 1 Series C - II | Venture Capital | New York | ||
4/9/2015 | 4/9/2015 | 1 Series C - II | Asset/Investment Management | Colorado | ||
4/9/2015 | 4/9/2015 | 1 Series C - II | Corporate Venture | California | ||
Venture Capital | California | |||||
Venture Capital | California |
First funding | 4/9/2015 | 4/9/2015 | 4/9/2015 | ||
|---|---|---|---|---|---|
Last Funding | 4/9/2015 | 4/9/2015 | 4/9/2015 | ||
Investor | |||||
Rounds | 1 Series C - II | 1 Series C - II | 1 Series C - II | ||
Board Seats | |||||
Type | Venture Capital | Asset/Investment Management | Corporate Venture | Venture Capital | Venture Capital |
Location | New York | Colorado | California | California | California |
Edge Therapeutics Acquisitions
1 Acquisition
Edge Therapeutics acquired 1 company. Their latest acquisition was PDS Biotechnology on March 18, 2019.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
3/18/2019 | Other Venture Capital | $6.07M | Reverse Merger | 5 |
Date | 3/18/2019 |
|---|---|
Investment Stage | Other Venture Capital |
Companies | |
Valuation | |
Total Funding | $6.07M |
Note | Reverse Merger |
Sources | 5 |
Compare Edge Therapeutics to Competitors
Imagine Pharmaceuticals is developing technology to facilitate delivery of drugs to the brain
Travanti Pharma is a medical device company specializing in the development and sale of microneedle array products for the healthcare sector. Their main offering includes the AdminPen2 hollow microneedle injection device, designed for self-administrable drug delivery without the need for reformulating existing drug formulations. The company primarily serves sectors that require drug delivery solutions, such as oncology, immunology, and transdermal therapy. It was founded in 1997 and is based in Mendota Heights, Minnesota.
Travanti offers transdermal delivery of drugs and cosmetic agents utilizing active-patch technology.
FORMAC Pharmaceuticals N.V. is a company engaged in the pharmaceutical industry. The company specializes in silica-based drug delivery platforms intended to improve the performance of poorly soluble drugs. FORMAC Pharmaceuticals collaborates with pharmaceutical and animal health companies. It was founded in 2007 and is based in Belgium.
Optinose is a pharmaceutical company that develops products for patients with ear, nose, and throat (ENT) conditions and allergies. The company offers an exhalation delivery system (EDS) that delivers a corticosteroid to treat chronic rhinosinusitis with nasal polyps and is in the process of seeking approval for chronic rhinosinusitis without nasal polyps. It serves the healthcare industry by focusing on products for ENT and allergy specialists. Optinose was founded in 2000 and is based in Yardley, Pennsylvania. On May 21, 2025, it was acquired by Paratek Pharmaceuticals.
Westfield Life Sciences Fund invests in healthcare companies across the capitalization spectrum including medical devices, drugs, drug delivery, biotechnology, and healthcare services. Portfolio manager Will Muggia employs a fundamental, bottom up research driven process that focuses on preservation of capital and long-term outperformance. The company was founded in 2000 and is based in Boston, Massachusetts.
Loading...